A comprehensive view of Inflammations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Novartis acquires IFM Therapeutics subsidiary IFM Due for US$90.0M upfront, plus potential milestones totaling US$835.0M; Novartis gets full rights to the STING antagonist program developed in a four-year research collaboration
Published: March 13, 2024 by Associated Press
New findings in food allergies reveal the immunomodulatory role of milk-derived bioactive peptides; the study highlights the potential health benefits of these peptides in regulating inflammatory balance in food allergy: Nanchang University, China
Published: March 13, 2024 by Health & Medicine Daily
Sun Pharma's US branch recalls 55,272 bottles of febuxostat gout tablets due to microbial contamination at its Dadra, India, manufacturing facility; recall covers 40-milligram and 80-milligram dosages
Published: March 11, 2024 by FiercePharma
FDA approves Fresenius Kabi's Tyenne, a biosimilar tocilizumab drug for inflammatory and immune diseases referencing Actemra tocilizumab in both IV and subcutaneous formulations; this marks the company's third biosimilar approval in the US
Published: March 08, 2024 by ENP Newswire
Almirall acquires global rights to develop and market Novo Nordisk's IL-21 blocking monoclonal antibody, NN-8828, for immune inflammatory dermatological diseases; Almirall to explore the new approach of IL-21 blockage as a treatment for skin disorders
Published: February 27, 2024 by Wireless News

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count